# Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

> **NCT01538329** · PHASE2 · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 210 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Amantadine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01538329
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-04
- **Primary completion:** 2018-02-20
- **Final completion:** 2019-02-26
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538329, "Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01538329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*